Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.50
-0.24 (-1.52%)
At close: Apr 23, 2026, 4:00 PM EDT
15.40
-0.10 (-0.65%)
After-hours: Apr 23, 2026, 6:53 PM EDT
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
2.02B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Ascentage Pharma Group International | 767 |
| Adaptive Biotechnologies | 624 |
| Galapagos NV | 558 |
| Ocular Therapeutix | 325 |
| Zymeworks | 264 |
| Capricor Therapeutics | 231 |
| Stoke Therapeutics | 170 |
MESO News
- 9 days ago - Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - GlobeNewsWire
- 13 days ago - Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION - GlobeNewsWire
- 15 days ago - Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation - GlobeNewsWire
- 15 days ago - Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - GlobeNewsWire
- 17 days ago - Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter - GlobeNewsWire
- 5 weeks ago - Mesoblast to Host R&D Day on April 8, 2026 - GlobeNewsWire
- 6 weeks ago - Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast - GlobeNewsWire
- 2 months ago - Ryoncil® Profits Underpinning Substantial Growth Pipeline - GlobeNewsWire